Cellectis S.A. (NASDAQ:CLLS)’s share price rose 20.6% during trading on Tuesday . The company traded as high as $32.46 and last traded at $25.55. Approximately 3,105,543 shares were traded during mid-day trading, an increase of 2,531% from the average daily volume of 118,032 shares. The stock had previously closed at $32.18.

A number of equities research analysts have recently issued reports on CLLS shares. Zacks Investment Research upgraded Cellectis from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a research note on Wednesday, July 19th. Oppenheimer Holdings, Inc. set a $40.00 target price on Cellectis and gave the company a “buy” rating in a research note on Wednesday, May 10th. BidaskClub upgraded Cellectis from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 23rd. SunTrust Banks, Inc. lowered Cellectis from a “buy” rating to a “hold” rating and lowered their target price for the company from $35.00 to $20.00 in a research note on Tuesday. Finally, Jefferies Group LLC set a $47.00 target price on Cellectis and gave the company a “buy” rating in a research note on Friday, August 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Cellectis presently has an average rating of “Buy” and a consensus target price of $39.00.

The stock’s 50 day moving average price is $24.86 and its 200-day moving average price is $24.10. The company’s market capitalization is $895.12 million.

Several institutional investors have recently bought and sold shares of the company. Williams Jones & Associates LLC bought a new position in shares of Cellectis in the second quarter worth about $244,000. Balyasny Asset Management LLC bought a new position in shares of Cellectis in the second quarter worth about $719,000. ARK Investment Management LLC increased its stake in shares of Cellectis by 79.1% in the second quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,784 shares during the period. Wells Fargo & Company MN increased its stake in shares of Cellectis by 132.1% in the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 5,435 shares during the period. Finally, Sphera Funds Management LTD. increased its stake in shares of Cellectis by 27.6% in the second quarter. Sphera Funds Management LTD. now owns 203,764 shares of the biotechnology company’s stock worth $5,261,000 after purchasing an additional 44,100 shares during the period. Institutional investors and hedge funds own 14.85% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/09/07/cellectis-s-a-clls-stock-price-up-20-6-2.html.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.